Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group
Frank V. Fossella(Ontario Institute for Cancer Research), Chandra P. Belani(Pennsylvania State University), Joachim von Pawel(Asklepios Fachkliniken München-Gauting), A Płużańska(Fundación Instituto Valenciano de Oncología), K. Mattson(Asklepios Fachkliniken München-Gauting), P. Fidias(Asklepios Fachkliniken München-Gauting), Jose R. Pereira(Ontario Institute for Cancer Research), Michael Millward(University of Western Australia), E. Kaukel(Heidelberg University), Vera Gorbounova(Russian Cancer Research Center NN Blokhin), Aleksandra Szczęsna(Chinese University of Hong Kong), Rodryg Ramlau(Poznan University of Medical Sciences)
Cited by 943
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k